Is CI a Buy? What to Consider in 2026

Last updated June 2026

Short answer

There is no universal answer to whether CI is a buy; it depends on your thesis, time horizon, and what you already own. Below is the case for The Cigna Group, the main risks to weigh, where the stock trades, and a framework to decide for yourself. This is informational, not a recommendation, and Walnut is not an investment adviser.

The Cigna Group is a large US health-services company built around two main engines. Its Evernorth health-services arm includes Express Scripts, one of the largest pharmacy benefit managers (PBMs) in the country, plus specialty pharmacy, care services, and pharmacy-related businesses; this is now the larger revenue and growth driver. Its Cigna Healthcare arm sells commercial health insurance, primarily to employers and individuals, along with international and supplemental coverage. Cigna makes money by collecting insurance premiums and managing medical costs, and by earning fees and spreads on managing drug benefits, negotiating with manufacturers, and dispensing specialty medications at scale. After exiting most of its Medicare businesses, Cigna is increasingly weighted toward commercial insurance and pharmacy services rather than government programs. It is headquartered in Bloomfield, Connecticut, and serves employers, health plans, government entities, and individuals.

The case for The Cigna Group

1. Evernorth and pharmacy services scale.

Evernorth, anchored by Express Scripts, is Cigna's growth engine. As one of the largest PBMs, it commands enormous negotiating scale with drug manufacturers, and its fast-growing specialty pharmacy business benefits from the rising volume of high-cost specialty and biologic drugs. Expanding services across care delivery, behavioral health, and data give Cigna recurring, fee-based revenue beyond traditional insurance.

2. Stable commercial insurance core.

Cigna Healthcare focuses on employer-sponsored commercial coverage, which is generally more stable and profitable than government programs. By exiting most Medicare businesses, Cigna has reduced exposure to the medical-cost pressures hitting Medicare Advantage peers, sharpening its mix toward steadier commercial and stop-loss insurance.

3. Strong cash generation and capital returns.

The combined business produces substantial free cash flow, which Cigna deploys into a growing dividend and large share buybacks. Disciplined capital allocation and a meaningful repurchase program steadily reduce the share count, supporting per-share earnings growth even when underlying volumes grow modestly.

4. Specialty drug tailwind.

The shift toward expensive specialty and biologic therapies, including GLP-1 weight-loss drugs, increases the value of Cigna's pharmacy management, specialty dispensing, and cost-control capabilities. Evernorth is positioned to manage and profit from this rising drug spend on behalf of employers and health plans.

The risks to weigh

Cigna faces significant regulatory and political risk: PBMs are under scrutiny from Congress, the FTC, and states over drug-pricing practices and rebate models, and potential reform could pressure the economics of Express Scripts. Health insurers also face rising medical-cost trends and utilization, which can squeeze margins. Concentration in a few large clients (including a major contract with Centene-related and Cigna's own plans) and reliance on retaining big PBM clients add risk. Drug-pricing reform, GLP-1 cost dynamics, litigation, and competitive pressure from vertically integrated rivals like UnitedHealth and CVS all weigh on the outlook. The stock often trades at a low multiple reflecting these regulatory overhangs.

Valuation context (as of early 2026)

Revenue (TTM): ~$250 billion (inflated by pharmacy pass-through revenue)
Operating margin: thin on a revenue basis (PBM pass-through), measured better on adjusted EPS
Adjusted EPS: double-digit growth targeted over time
Dividend yield: ~2%
P/E (TTM): low, often ~12-15x on forward earnings
Free cash flow: strong, funding large buybacks
Segments: Evernorth (pharmacy/health services) and Cigna Healthcare (insurance)

Cigna trades at a low earnings multiple relative to the broad market, a discount that reflects PBM regulatory risk and the optically huge but low-margin pharmacy pass-through revenue. The bull case leans on steady adjusted EPS growth, heavy buybacks, and Evernorth's scale; the discounted valuation is the market pricing in policy and drug-pricing uncertainty.

How to decide for yourself

Rather than asking whether CI is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold CI indirectly through an index or sector ETF before adding more.

For the full picture, see the CI stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CI against your real portfolio and see your actual exposure before deciding.

Build a basket around CI with Walnut

Use The Cigna Group as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is CI a good stock to buy right now?

There is no universal answer. Whether The Cigna Group fits depends on your thesis, time horizon, risk tolerance, and what you already own. This page lays out the case for, the main risks, and where the stock trades, so you can decide for yourself. Walnut is not an investment adviser and this is not a recommendation.

What does The Cigna Group do?

Health-services giant pairing Express Scripts pharmacy scale with commercial insurance, trading at a low valuation.

What are the main risks of CI?

What is CI's ticker symbol?

CI, listed on the New York Stock Exchange. The company is The Cigna Group, headquartered in Bloomfield, Connecticut. It trades during US market hours and is available at every major US brokerage.

What does Cigna do?

Cigna is a health-services company. Its Evernorth arm runs Express Scripts, a major pharmacy benefit manager, plus specialty pharmacy and care services, while Cigna Healthcare sells commercial health insurance to employers and individuals. It earns premiums and pharmacy-management fees and spreads.

Who are Cigna's main competitors?

In insurance, UnitedHealth, Elevance, CVS/Aetna, and Humana. In pharmacy benefit management, CVS Caremark and UnitedHealth's OptumRx. In specialty pharmacy and health services, CVS and Optum.

What is a PBM and why does it matter for CI?

A pharmacy benefit manager negotiates drug prices and rebates and manages prescription benefits for employers and health plans. Cigna's Express Scripts is one of the three largest PBMs. PBMs are Cigna's biggest growth driver but also its biggest regulatory risk.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CI; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.